You are here: Industry Insights > eliquis

News List

BMS 2Q Revenues up 16% contractpharma
August 02, 2021
Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.
FDA approves first generics of Eliquis americanpharmaceuticalreview
December 24, 2019
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients ...
Top 10 Small Molecule Drugs: A Half were Oncology Drugs PharmaSources/Yuntian
April 24, 2019
Small molecule drugs still have a huge share in the global market at present, and are the biggest source of drugs.
BMS, Pfizer's Eliquis tops warfarin in high-risk afib subgroup fiercepharma
March 19, 2019
Pfizer and Bristol-Myers Squibb’s next-gen anticoagulant Eliquis has been stealing warfarin market share for years, but that doesn't mean it's slowing down.
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive fiercepharma
July 31, 2018
Last year, Pfizer and Bristol-Myers Squibb’s Eliquis replaced Johnson & Johnson’s Xarelto as the leader of the novel oral anticoagulant class. And now it’s about to unseat an even bigger foe: warfarin.
Bristol-Myers Squibb beats Street revenue, EPS estimates in Q4 as Eliquis surges fiercepharma
February 06, 2018
The same day Bristol-Myers Squibb reported a closely watched trial win for cancer combo Opdivo-plus-Yervoy in certain lung cancer patients, the drugmaker announced 2017 results, beating expectations with Opdivo and anticoagulant Eliquis.